InterOcean Capital LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 60.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,105 shares of the medical research company’s stock after acquiring an additional 1,550 shares during the period. InterOcean Capital LLC’s holdings in Thermo Fisher Scientific were worth $850,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. FNY Investment Advisers LLC purchased a new position in Thermo Fisher Scientific in the second quarter worth about $103,000. Horrell Capital Management Inc. purchased a new position in Thermo Fisher Scientific in the second quarter worth about $104,000. Johnson Financial Group Inc. raised its holdings in Thermo Fisher Scientific by 2,608.7% in the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock worth $129,000 after buying an additional 600 shares during the last quarter. Edge Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 8,077.8% in the second quarter. Edge Wealth Management LLC now owns 736 shares of the medical research company’s stock worth $152,000 after buying an additional 727 shares during the last quarter. Finally, Private Capital Group LLC raised its holdings in Thermo Fisher Scientific by 57.3% in the first quarter. Private Capital Group LLC now owns 865 shares of the medical research company’s stock worth $179,000 after buying an additional 315 shares during the last quarter. 85.93% of the stock is owned by institutional investors.

TMO opened at $235.96 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.58 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a twelve month low of $181.51 and a twelve month high of $240.88. The company has a market cap of $94.95 billion, a PE ratio of 24.86, a P/E/G ratio of 1.72 and a beta of 1.12.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 25th. The medical research company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.12. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The firm had revenue of $6.08 billion during the quarter, compared to analysts’ expectations of $5.90 billion. During the same period in the previous year, the company earned $2.30 earnings per share. The firm’s quarterly revenue was up 21.8% on a year-over-year basis. research analysts predict that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 15th. Stockholders of record on Monday, September 17th will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s payout ratio is 7.17%.

In other news, CEO Marc N. Casper sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $214.80, for a total transaction of $9,666,000.00. Following the completion of the transaction, the chief executive officer now directly owns 315,122 shares of the company’s stock, valued at $67,688,205.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick M. Durbin sold 20,550 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $233.87, for a total transaction of $4,806,028.50. The disclosure for this sale can be found here. Insiders have sold 165,550 shares of company stock valued at $37,055,029 over the last three months. 0.49% of the stock is owned by corporate insiders.

Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, July 24th. Leerink Swann lifted their target price on shares of Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $230.00 to $233.00 and gave the stock an “overweight” rating in a report on Friday, July 13th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 26th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $239.08.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Hedge Funds Explained

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.